The intravenous iron preparation Rienso (ferumoxytol) has been withdrawn for commercial reasons. Launched in 2012, it was licensed for the treatment of iron deficiency anaemia in patients with chronic kidney disease.
Rienso (ferumoxytol) withdrawn

This site is intended for healthcare professionals
The intravenous iron preparation Rienso (ferumoxytol) has been withdrawn for commercial reasons. Launched in 2012, it was licensed for the treatment of iron deficiency anaemia in patients with chronic kidney disease.
The most up-to-date drug information at your fingertips.
Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.
Loss of taste and smell and neurological aspects of...
Use our constantly updated shortages tracker to check...
Use our timeline to follow the latest coronavirus developments...
Trimbow (beclometasone/formoterol/glycopyrronium) can...